FDA Releases Updated Good Clinical Practice Guidance for Trials
Published Date: 9/9/2025
Notice
Summary
The FDA just released the final version of the E6(R3) Good Clinical Practice guidance, which helps drug makers run safer, smarter clinical trials using modern tech and risk-based methods. This update affects anyone involved in clinical trials by encouraging simpler, quality-focused approaches that save time and resources. Get ready to follow these new rules soon to keep trials efficient and reliable!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Modernized Good Clinical Practice Rules
The FDA released the final E6(R3) Good Clinical Practice guidance, which outlines flexible, modern rules for running clinical trials. It emphasizes quality-by-design, proportionality, and risk-based approaches, encourages use of innovative technology, and finalizes the draft issued June 7, 2023; annex 2 will be added later.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-17308 — New England Fishery Management Council; Public Meeting
The New England Fishery Management Council is hosting a 3-day meeting where people can join in person or online to talk about rules for fishing in New England waters. This affects fishermen, seafood businesses, and anyone who loves fresh fish from the area. They’ll discuss important changes soon, so keep an eye out for new fishing rules that could impact when and how much fish can be caught.
Next: 2025-17312 — Record of Decision for the Enhanced Integrated Air and Missile Defense System on Guam Environmental Impact Statement
The U.S. is moving forward with building and running a new, super-smart missile defense system on Guam to protect against fast-changing threats. This plan affects the military, local communities, and the environment, with careful steps to reduce any harm. Construction and operations will start soon, backed by strong government support and funding to keep Guam safe.